title: Emerging drugs for the treatment of cervical cancer.
abstract: BACKGROUND
  Worldwide, most cervical cancer (CC) patients require the use of drug therapy either adjuvant, concurrent with radiation or palliative.
  
  
  METHODS
  This review briefly discusses the current achievements in treating CC with an emphasis in emerging agents.
  
  
  CONCLUSIONS
  Concurrent cisplatin with radiation and lately, gemcitabine-cisplatin chemoradiation has resulted in small but significant improvements in the treatment of locally advanced and high-risk early-stage patients. So far, only antiangiogenic therapy with bevacizumab added to cisplatin chemoradiation has demonstrated safety and encouraging results in a Phase II study. In advanced disease, cisplatin doublets yield median survival rates not exceeding 14 months. The first Phase III study of bevacizumab, added to standard chemotherapy cisplatin- or non-cisplatin-containing doublet, has shown significant increase in both overall survival and progression-free survival. Further studies are needed before bevacizumab plus chemotherapy can be considered the standard of care for advanced disease. The characterization of the mutational landscape of CC and developments of novel targeted therapies may result in more effective and individualized treatments for CC. The potential efficacy of knocking down the key alterations in CC, E6 and E7 human papilloma virus oncoproteins must not be overlooked.
authors.affiliation: ABC Medical Center , Mexico City , México.
authors.forename: Alberto
authors.initials: A
authors.lastname: Serrano-Olvera
authors.forename: Lucely
authors.initials: L
authors.lastname: Cetina
authors.forename: Jaime
authors.initials: J
authors.lastname: Coronel
authors.forename: Alfonso
authors.initials: A
authors.lastname: Dueñas-González
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D018572:Disease-Free Survival; D015195:Drug Design; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D057285:Precision Medicine; D013534:Survival; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents
keywords: E6/E7 oncogenes; advanced cervical cancer; chemoradiation; chemotherapy; histone deacetylase inhibitors; human papilloma virus; locally advanced cervical cancer; monoclonal antibodies; novel cytotoxics; radiosensitizers; tyrosine kinase inhibitors